FIELD: medicine.
SUBSTANCE: invention concerns weight loss therapy with semaglutide.
EFFECT: invention provides an unexpectedly improved relationship between improved weight loss and safety profile in terms of gastrointestinal adverse events.
11 cl, 2 ex, 9 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| SEMAGLUTIDE IN CARDIOVASCULAR CONDITIONS | 2017 |
|
RU2768283C2 |
| USE OF LONG-ACTING GLP-1 PEPTIDES | 2013 |
|
RU2657573C2 |
| GLP-1-BASED COMPOSITIONS AND THEIR APPLICATION METHODS | 2018 |
|
RU2777600C2 |
| LIXISENATIDE AND METFORMIN FOR TYPE 2 DIABETES TREATMENT | 2012 |
|
RU2623023C2 |
| STABLE COMPOSITIONS BASED ON SEMAGLUTIDE AND THEIR USE | 2019 |
|
RU2803237C2 |
| TREATING LIVER DISEASE OR DISORDER INVOLVING USE OF ACTRII RECEPTOR ANTAGONISTS | 2020 |
|
RU2838150C1 |
| LYRAGLUTIDE FOR CARDIOVASCULAR DISEASE | 2017 |
|
RU2745604C2 |
| METHOD OF WEIGHT REDUCTION | 2013 |
|
RU2664442C2 |
| PREVENTING HYPOGLYCAEMIA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS | 2012 |
|
RU2572703C2 |
| PHARMACEUTICAL COMBINATION FOR USE FOR INDUCING WEIGHT LOSS IN SUBJECTS WITH TYPE 2 DIABETES OR/AND FOR PREVENTING WEIGHT GAIN IN SUBJECTS WITH TYPE 2 DIABETES | 2012 |
|
RU2761624C2 |
